

2 November 2016

ASX ANNOUNCEMENT

BIOXYNE LAUNCHES TWO PRODUCTS CONTAINING PCC® ONTO THE AUSTRALIAN MARKET

Bioxyne Limited (ASX:BXN) (the Company or Bioxyne) is pleased to announce that it has today launched its first two own brand probiotic products, Progastrim®, a probiotic product for gut and immune health, and proTract® for atopic dermatitis (eczema) in the Australian market. Initially they will only be available on-line at www.progastrim.com and www.protract.com.au. Bioxyne plans to also make it available in Australian pharmacies soon, subject to ongoing negotiations.

Both products contain Bioxyne's patented probiotic, PCC®, a strain of *Lactobacillus fermentum* that has been shown in several Australian scientific and clinical studies to promote gastrointestinal health and to reduce severity and duration of cold symptoms when taken orally.

Progastrim®, which is sold in bottles of 30 capsules is listed on the Australian Register of Therapeutic Goods with the following claims:

May assist in:

- the maintenance or improvement of general well-being
- the maintenance of a normal healthy gastrointestinal system
- the maintenance of a normal healthy immune system

proTract® for Atopic Dermatitis, is a formulation of PCC® in sachets for infants from 6-18 months who are suffering symptoms of atopic dermatitis, or eczema. This formulation was demonstrated in an Australian clinical study to significantly improve the symptoms of moderate to severe atopic dermatitis.

Bioxyne's Chairman Mr Tony Ho said, "It is pleasing to have our own probiotic products in our home market to bring the benefits of PCC® directly to Australians. We will also use the products to advance our marketing efforts into other markets including China. This is the first two of a number of products containing PCC® that the Company plans to bring to the market in the short to medium term."

Progastrim® is the subject of a current, further clinical trial in gastrointestinal health in healthy adults that the Company has recently announcedⁱ. The outcomes being examined are the effect of PCC® on the composition of the gut microbiome towards a healthy bacterial balance, on bowel function, weight loss and general well-being.

What is Atopic Dermatitis?

Atopic dermatitis is a common inflammatory skin disease affecting as many as 1 child in 5 (20%) in many countries, including Australia, the UK, New Zealand, Singapore, and parts of the US. In the US at least 18 million children have moderate to severe symptoms. In China and Europe the prevalence is around 8-10% of children. The signs of atopic dermatitis appear early in life (from 6 months of age) and include dry and scaly patches on the scalp, forehead, and face. These symptoms pose a significant burden on healthcare resources and on the patients' quality of life.

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian life sciences, health and medical technologies company (originated as VRI Biomedical Ltd in 2000) with a focus on immune health and immunotherapeutic products.

Bioxyne has a strategic investment in the consumer dietary supplements and functional foods markets through its proprietary probiotic, *Lactobacillus fermentum* PCC®. Bioxyne is a company creating value for consumers and investors by delivering safe and effective solutions.

Bioxyne's focus is currently on the company's probiotic business and proprietary product *Lactobacillus fermentum* PCC® which is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne also has a distribution agreement with Nu-Skin Enterprises (USA) a successful worldwide multilevel marketing company who pride themselves in offering only quality solutions to their customers.

Guy Robertson, Chief Operating Officer, Bioxyne Limited
+61 2 9078 8180 or +61 407 983 270

Dr. Peter French, Scientific Director, Bioxyne Limited
+61 2 9078 8180 or +61 412 457 595

ⁱ See ASX Announcement 17 October 2016